Must-read news from the week of May 16

A look at what the Contemporary Pediatrics® team covered this week.

This week’s top articles:

Donna Hallas discusses the Pfizer-BioNTech vaccine booster for children 5 to 11 years old

Contemporary Pediatrics® Editorial Advisory Board member Donna Hallas shares her thoughts on the recent authorization of a Pfizer-BioNTech COVID-19 booster shot for children 5-11 years old.

Butyrylcholiesterase may be key biomarker in SIDS identification, prevention

Investigators may have found a piece of the puzzle into what causes sudden infant death syndrome.

FDA implements increased flexibilities for foreign importation of infant formula

This week, the agency announced it is encouraging importation of infant formula from usually unutilized foreign means in hopes of increasing access to the product in the wake of the country-wide shortage.

House of Representatives democrats propose $28 million aid bill for infant formula shortage

The proposed aid bill would give the FDA funds to increase staff and prepare for future infant formula shortages.

More articles from this week:

Getting to the heart of pediatric vision loss and blindness

Misinformation and acne

Seconds Matter: A Pearl for Improving Communication During Surgery

Study examines best practices for managing perinatal depression

Significant OSA prevalence in pediatric patients with pulmonary hypertension

First patient treated in adolescent epilepsy trial assessing NeuroPace RNS system

FDA Authorizes Pfizer-BioNTech Booster Shot for Children Ages 5 to 11

Self-tests for COVID-19 are accurate and tolerable for children

Sunscreen protection for children

Pfizer-BioNTech vaccine prevented more than 100,000 US deaths in 2021

Preexisting CV conditions may increase COVID-19 severity among pediatric patients

Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI

AAP advocates for increased action from White House, Congress on infant formula shortage